Alcoholism & Drug Abuse Weekly
GAO: DEA, FDA lack procedures guiding drug scheduling decisions
By Gary A. Enos.
Abstract
At a time when addiction field professionals and advocates await a decision on the possible rescheduling of marijuana, a report from Congress's Government Accountability Office (GAO) has uncovered gaps in the overall evaluations conducted by the federal agencies involved in all drug scheduling decision‐making processes.
Keywords
- Opioid Use Disorder Treatment
- drug scheduling
- Controlled Substances Act
- Drug Enforcement Administration
- Food and Drug Administration
- federal drug policy
- evaluation procedures